Pfizer Reshapes Portfolio With Obesity Bet, Vaccine Deal And Pricing Shift [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The company signed a licensing deal with Novavax for access to its Matrix-M vaccine adjuvant technology. Pfizer also joined the TrumpRx U.S. drug pricing initiative, which focuses on deep medication discounts. For you as an investor, these moves sit at the intersection of some of the most closely watched themes in healthcare, including obesity treatments, vaccines and drug pricing. Pfizer, known for its broad prescription drug and vaccine portfolio, is responding to fading COVID-19 product revenues and looming patent expirations by adding new areas of focus that could change its mix of businesses over time. The Metsera deal puts Pfizer into the GLP-1 obesity drug space, while the Novavax agreement extends its options in future vaccine development. Participation in TrumpRx highlights how pricing pressure in the U.S. is influencing large pharmaceutical compa
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story [Yahoo! Finance]Yahoo! Finance
- Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts [Yahoo! Finance]Yahoo! Finance
- BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets [Yahoo! Finance]Yahoo! Finance
- Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? [Seeking Alpha]Seeking Alpha
- Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 1/26/26 - Form 4
- 1/20/26 - Form 8-K
- 1/12/26 - Form 8-K
- NVAX's page on the SEC website